We have upgraded our Computational Analysis of Novel Drug Opportunities (CANDO) 2 platform for shotgun drug repurposing to include ligand-based, data fusion, and decision tree 3 pipelines. The first version of CANDO implemented a structure-based pipeline that mod-4 eled interactions between compounds and proteins on a large scale, generating compound-5 proteome interaction signatures used to infer similarity of drug behavior; the new pipelines 6 accomplish this by incorporating molecular fingerprints and the Tanimoto coefficient. We 7 obtain improved benchmarking performance with the new pipelines across all three evalua-8 tion metrics used: average indication accuracy, pairwise accuracy, and coverage. The best 9 performing pipeline achieves an average indication accuracy of 19.0% at the top10 cutoff, 10 compared to 11.7% for v1, and 2.2% for a random control. Our results demonstrate that the 11 CANDO drug recovery accuracy is substantially improved by integrating multiple pipelines, 12 thereby enhancing our ability to generate putative therapeutic repurposing candidates, and 13 increasing drug discovery efficiency. 14 Introduction 15 Drug repurposing 16 Bringing a new drug to the market may costs hundreds of millions of dollars and takes years 17 of work. 1 Drug repurposing is the process of discovering a new use for an existing drug. 2,3 18
: Flow diagram of the CANDO platform pipelines used for shotgun drug repurposing. The v1 structure-based pipeline is the original protein-centric approach based on a bioinformatic docking protocol used to construct compound-proteome interaction signatures. The ligand-based pipelines are based on molecular fingerprint representations of compounds. The data fusion pipelines consist of a combination these two types of pipelines after calculating compound-compound similarity, and the decision tree pipeline is devised based on the performance of individual structure-and ligand-based pipelines (see Methods). All pipelines, except the decision tree pipeline, generate a compound-compound similarity matrix that is sorted and ranked. These rankings are used to generate putative repurposable drug candidates and evaluate benchmarking performance. The figure illustrates the utility of implementing, as well as comparing and contrasting, multiple (types of) pipelines in the CANDO platform for shotgun drug repurposing.
as Extended Connectivity Fingerprints (ECFP, a circular fingerprint), one Functional Class based pipelines in CANDO are identified according to the molecular fingerprint used, i.e.,
180
"ECFP4" refers to the CANDO pipeline where compounds are represented using the ECFP4 181 molecular fingerprint.
182
Hert et al. found the optimal results for quantifying relationships between drug classes 183 was achieved using ECFP4 fingerprints with similarities calculated using the Tanimoto coeffi-184 cient. 59 We extended this to ligand-based drug repurposing using vectors of 2048 bits instead 185 of the 1024 used in. 59 We calculated the Tanimoto coefficient between the fingerprints of all 186 possible pairs of the 3733 compounds in our library, and used this to populate a compound-187 compound similarity matrix, just as we did with the v1 pipeline, allowing us to sort and 188 rank all compounds relative to each other. Fingerprints could not be created for twelve of 189 the 3733 compounds in our putative drug library, which were generally large compounds 190 with metal chelation or long polymers. We then evaluated benchmarking performance of the 191 ligand-based pipelines as described further below.
192
Data fusion pipelines 193 We combined rankings from the v1 pipeline with the new molecular fingerprint rankings using 194 one of the following criteria: lower of two rankings (MIN), higher of two rankings (MAX), 195 sum of two rankings (SUM), average of two rankings (AVG). This is known as "rank-based 196 data fusion". 69 We also combined the compound-compound similarity scores from v1 and 197 the ligand-based pipelines using the multiplication of raw similarity scores (MUL), a type of 198 "kernel-based data fusion". 69 After multiplying the similarity scores from two pipelines, the 199 compounds are sorted and ranked based on the newly calculated scores. As in v1 and the 200 ligand-based pipelines, the compound-compound rankings from these data fusion pipelines 201 is then subjected to benchmarking.
202

Decision tree pipeline 203
A goal of CANDO is to make predictions of which compounds are likely to be efficacious 204 against any particular indication. A second is to use analytics to identify causal relationships 205 that predict indication etiology. From the benchmarking, we can determine a priori the 206 pipeline that has the best performance for a particular indication, which are then used to 207 generate putative drug candidates for that indication. We constructed a new meta pipeline 208 that makes a decision as to optimal performance on a per indication basis. We made this 209 decision using the top10 average indication accuracy metric (described below), from two 210 choices, v1 and the best performing ligand-based pipeline, namely ECFP4 (see Results). We 211 used this to create a merged set of data which was then benchmarked. For example, the 212 v1 pipeline yields a top10 average indication accuracy of 25% for type 2 diabetes, whereas 213 ECFP4 yields a top10 accuracy of 35%. In the combined decision tree pipeline, we choose 214 to use ECFP4 for the prediction of repurposing candidates for type 2 diabetes, and for the 215 calculation of all benchmarking performance metrics at all cutoffs. We extended this method for each pipeline are shown at different cutoffs. The value for the top10 cutoff is denoted by dark purple, top25 by light purple, top1% (or top37) by yellow, top50 by green, and top100 by light blue. The individual pipeline with the best performance at each each cutoff is denoted by a red dot. The meta decision tree pipeline was built combining two pipelines, v1 and ECFP4, using the top10 average indication accuracy and so has the highest top10 accuracy and coverage, but is excluded by the "Best at cutoff" marker. The pipelines in all plots are sorted according to increasing top10 average indication accuracy, the most stringent criteria used in our benchmarking. The MUL:v1,ECFP4 pipeline yields the overall best performance relative to the other individual structure-and ligand-based pipelines. The pipeline based on the ECFP4 molecular fingerprint produces the highest top1% and top100 average indication accuracies (top). When assessing pairwise accuracy (middle), ECFP4 is the best performing individual pipeline. The coverage (bottom) plot is a percentage of the 1439 indications for which a pipeline produces a non-zero indication accuracy. The data fusion pipelines of MUL:v1,ECFP4 and MIN:v1,RDK6 have the highest coverage at the top50 and top25 cutoffs, the ECFP4 at the top10 and top50 cutoffs, and RDK6 at the top100 cutoff. Overall, the pipelines using molecular fingerprints have promise and potential for shotgun drug repurposing by themselves, but the data fusion and decision tree pipelines that combine structure-based and ligand-based approaches achieve the best performance while retaining the benefits of both types of approaches.
recovery of the known drug within a particular cutoff. The ECFP4 pipeline has the highest 274 top10 and top1% coverage of 45.9% and 54.2%, the MIN:v1,RDK6 yields the highest top25 275 coverage of 52.3%, the MUL:v1,ECFP4 has the highest coverage at the top50 cutoff of 56.9%, 276 and RDK6 the highest at the top100 cutoff of 62.8%. In contrast, the decision tree pipeline, 277 built in part to increase coverage, has a top10 coverage of 49.8%. This means that for almost 278 half of all the 1439 indications, we capture a drug associated with that indication within the 279 top10 cutoff (Figure 2) . The left hand side shows the histograms of the counts of indications with a particular average indication accuracy (or accuracy distributions) for two pipelines, v1 (purple) and ECFP4 (yellow). Indications where both pipelines perform equally well are indicated by brown. For example, at the top10 cutoff, there are approximately 200 indications which achieve an average accuracy between 10 and 20% using the v1 pipeline but just over 100 using ECFP4. At all cutoffs, a greater number of indications with higher accuracies is observed for the ECFP4 pipeline (increase in yellow along the horizontal axis). The p-value, derived from the Kolmogorov-Smirnov test statistic applied to the two distributions at each cutoff, indicates that they are significantly different. On the right hand side of the figure are Venn diagrams of the set of indications with higher accuracies at each cutoff (excluding indications with 0% accuracy). For example, at the top10 cutoff, there are 150 indications for which the v1 pipeline yields higher average indication accuracies, 445 for which the ECFP4 pipeline is higher, and 122 with the same performance. The ECFP4 pipeline performs better than v1 for more indications at all cutoffs, but both pipelines appear to be necessary to achieve the best performance across all indications for shotgun drug repurposing.
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